• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Clever Leaves Regains Compliance with Nasdaq Minimum Bid Price Requirement

    9/13/23 8:30:00 AM ET
    $CLVR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CLVR alert in real time by email

    TOCANCIPÁ, Colombia, Sept. 13, 2023 (GLOBE NEWSWIRE) -- Clever Leaves Holdings Inc. (NASDAQ:CLVR, CLVRW))) ("Clever Leaves" or the "Company"), a global medicinal cannabis company, announced that it received notice from The Nasdaq Stock Market LLC ("Nasdaq") on September 11, 2023 informing the Company that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) (the "Rule") for continued listing on the Nasdaq Capital Market.

    On September 29, 2022, Clever Leaves received notice from Nasdaq that the Company was not in compliance with the Rule, as its common shares failed to meet a closing bid price of $1.00 or more for 30 consecutive business days. Clever Leaves received an additional 180 calendar day period to regain compliance on March 29, 2023, and the Company conducted a 1-for-30 reverse split of its common shares with marketplace effectiveness on August 25, 2023 to aid the compliance process.

    To regain compliance with the Rule, the Company's common shares were required to maintain a minimum closing bid price of $1.00 or more for at least 10 consecutive business days. This requirement was met on September 8, 2023.

    About Clever Leaves Holdings Inc.

    Clever Leaves is a global medical cannabis company. Its operations in Colombia produce EU GMP cannabinoid active pharmaceutical ingredients (API) and finished products in flower and extract form to a growing base of B2B customers around the globe. Clever Leaves aims to disrupt the traditional cannabis production industry by leveraging environmentally sustainable, ESG-friendly, industrial-scale and low-cost production methods, with the world's most stringent pharmaceutical quality certifications. Clever Leaves announces material information to the public through a variety of means, including filings with the Securities and Exchange Commission (the "SEC"), press releases, public conference calls, and its website (https://cleverleaves.com). Clever Leaves uses these channels, as well as social media, including its Twitter account (@clever_leaves), and its LinkedIn page (https://www.linkedin.com/company/clever-leaves), to communicate with investors and the public about Clever Leaves, its products, and other matters. Therefore, Clever Leaves encourages investors, the media, and others interested in Clever Leaves to review the information it makes public in these locations, as such information could be deemed to be material information. Information on or that can be accessed through Clever Leaves' websites or these social media channels is not part of this release, and references to Clever Leaves' website addresses and social media channels are inactive textual references only.

    Forward-Looking Statements

    This press release includes certain statements that are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as "aim," "anticipate," "believe," "can," "continue," "could," "estimate," "evolve," "expect," "forecast," "future," "guidance," "intend," "may," "opportunity," "outlook," "pipeline," "plan," "predict," "potential," "projected," "seek," "seem," "should," "will," "would" and similar expressions (or the negative versions of such words or expressions) that predict or indicate future events or trends or that are not statements of historical matters. Such forward-looking statements as well as our outlook for 2023 are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. Important factors that may affect actual results or the achievability of the Company's expectations include, but are not limited to: (i) our ability to continue as a going concern; (ii) our ability to maintain the listing of our securities on Nasdaq; (iii) our expectation that the reverse share split will bring us into compliance with Nasdaq's listing rules; (iv) our ability to implement our restructuring initiatives; (v) expectations with respect to future operating and financial performance and growth, including if or when Clever Leaves will become profitable; (vi) Clever Leaves' ability to execute its business plans and strategy and to receive regulatory approvals (including its goals in its five key markets); (vii) Clever Leaves' ability to capitalize on expected market opportunities, including the timing and extent to which cannabis is legalized in various jurisdictions; (viii) global economic and business conditions, including recent economic sanctions against Russia and their effects on the global economy; (ix) geopolitical events (including the ongoing military conflict between Russia and Ukraine), natural disasters, acts of God and pandemics, including the economic and operational disruptions and other effects of COVID-19; (x) regulatory developments in key markets for the Company's products, including international regulatory agency coordination and increased quality standards imposed by certain health regulatory agencies, and failure to otherwise comply with laws and regulations; (xi) uncertainty with respect to the requirements applicable to certain cannabis products as well as the permissibility of sample shipments, and other risks and uncertainties; (xii) consumer, legislative, and regulatory sentiment or perception regarding Clever Leaves' products; (xiii) lack of regulatory approval and market acceptance of Clever Leaves' new products which may impede its ability to successfully commercialize its products; (xiv) the extent to which Clever Leaves' is able to monetize its existing THC market quota within Colombia; (xv) demand for Clever Leaves' products and Clever Leaves' ability to meet demand for its products and negotiate agreements with existing and new customers, including the sales agreements identified as a part of the Company's 2023 strategic growth objectives; (xvi) developing product enhancements and formulations with commercial value and appeal; (xvii) product liability claims exposure; (xviii) lack of a history and experience operating a business on a large scale and across multiple jurisdictions; (xix) limited experience operating as a public company; (xx) changes in currency exchange rates and interest rates; (xxi) weather and agricultural conditions and their impact on the Company's cultivation and construction plans, (xxii) Clever Leaves' ability to hire and retain skilled personnel in the jurisdictions where it operates; (xxiii) Clever Leaves' ability to remediate a material weakness in its internal control cover financial reporting and to develop and maintain effective internal and disclosure controls; (xxiv) potential litigation; (xxv) access to additional financing; and (xxvi) completion of our construction initiatives on time and on budget. The foregoing list of factors is not exclusive. Additional information concerning certain of these and other risk factors is contained in Clever Leaves' most recent filings with the SEC. All subsequent written and oral forward-looking statements concerning Clever Leaves and attributable to Clever Leaves or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements above. Readers are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Clever Leaves expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in its expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.

    Clever Leaves Investor Inquiries:

    Cody Slach or Jackie Keshner

    Gateway Group, Inc.

    +1-949-574-3860

    [email protected]

    Clever Leaves Press Contact:

    Maria Petsanas

    KCSA Strategic Communications

    +1-917-692-6673

    [email protected]

    Clever Leaves Commercial Inquiries:

    Andrew Miller

    Head of Global Business Development

    +1-416-817-1336

    [email protected]



    Primary Logo

    Get the next $CLVR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CLVR

    DatePrice TargetRatingAnalyst
    12/23/2021$12.00 → $10.00Buy
    Canaccord Genuity
    11/12/2021$13.00 → $12.00Buy
    Canaccord Genuity
    7/27/2021$13.00Buy
    Canaccord Genuity
    7/23/2021Market Perform
    Cowen
    More analyst ratings

    $CLVR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Clever Leaves Announces Voluntary Delisting and SEC Deregistration

      TOCANCIPÁ, Colombia, April 26, 2024 (GLOBE NEWSWIRE) -- Clever Leaves Holdings Inc. (NASDAQ:CLVR, CLVRW))) ("Clever Leaves" or the "Company"), a global medicinal cannabis company, today announced that its Board of Directors (the "Board") determined to voluntarily delist its common shares, without par value (the "common shares") and warrants, each exercisable for 1/30th common share at an exercise price of $11.50 (the "Warrants" and together with the common shares, the "Securities") from The Nasdaq Stock Market LLC ("Nasdaq") and deregister its Securities in order to terminate and suspend its reporting obligations under the Securities and Exchange Act of 1934, as amended (the "Exchange Act"

      4/26/24 4:10:00 PM ET
      $CLVR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Clever Leaves Reports Fourth Quarter and Full Year 2023 Results

      - 2023 Revenue Increased 6% Year-Over-Year, with a 39% Increase in Full-Year Cannabinoid Revenue - - Drove Year-over-Year General and Administrative Expense Reductions of 26% in Q4 2023 and 24% for the Full Year - - Completed Sale of Non-Cannabinoid Herbal Brands Business on March 21, 2024 for $8.02 Million, Including $7.02 Million in Cash Paid at Closing - TOCANCIPÁ, Colombia, April 01, 2024 (GLOBE NEWSWIRE) -- Clever Leaves Holdings Inc. (NASDAQ:CLVR, CLVRW))) ("Clever Leaves" or the "Company"), a global medicinal cannabis company, is reporting financial and operating results for the fourth quarter and full year ended December 31, 2023. All financial information is provided in US doll

      4/1/24 4:01:00 PM ET
      $CLVR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Clever Leaves and Paradise Seeds to Develop and Register Genetic Assets in Colombia

      TOCANCIPÁ, Colombia, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Clever Leaves Holdings Inc. (NASDAQ:CLVR, CLVRW))) ("Clever Leaves" or the "Company"), a global medicinal cannabis company, announced today that through its partnership with award-winning Dutch seed bank, Paradise Seeds ("Paradise"), to develop and register high performance cannabis cultivars in Colombia, Clever Leaves will have exclusive license to cultivate some of these genetics, while Paradise will make other cultivars available to third parties for cultivation across Colombia and Latin America. The two companies have already begun rigorous selection, phenotyping, and agronomic trials of several Paradise varieties at Clever Leaves'

      2/13/24 8:30:00 AM ET
      $CLVR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CLVR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by Clever Leaves Holdings Inc. (Amendment)

      SC 13D/A - Clever Leaves Holdings Inc. (0001819615) (Subject)

      5/21/24 8:03:23 PM ET
      $CLVR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D filed by Clever Leaves Holdings Inc.

      SC 13D - Clever Leaves Holdings Inc. (0001819615) (Subject)

      5/15/24 9:11:49 PM ET
      $CLVR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Clever Leaves Holdings Inc. (Amendment)

      SC 13G/A - Clever Leaves Holdings Inc. (0001819615) (Subject)

      1/23/24 9:07:27 AM ET
      $CLVR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CLVR
    Financials

    Live finance-specific insights

    See more
    • Clever Leaves Reports Third Quarter 2023 Results

      - Q3 Revenue Increased 33% Year-Over-Year, Propelled by 135% Year-Over-Year Growth in Cannabinoid Revenue, Along with 6% Year-Over-Year Growth in Non-Cannabinoid Revenue - - Q3 Adjusted EBITDA Improved Year-Over-Year to $(2.6) Million Compared to $(3.7) Million, Reflecting Revenue Growth and Continued Aggressive Expense Reductions - - Cash Balance at October 31, 2023 was $6.2 Million, with $1.9 Million in Subsequent Capital Received from the November Sale of the Company's Remaining Stake in Cansativa - - Updated Full Year 2023 Guidance Reflects Revenue Timing Shifts, Revenue Mix, and Adjusted EBITDA Improvement from Continued Operating Efficiencies - TOCANCIPÁ, C

      11/9/23 4:01:00 PM ET
      $CLVR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Clever Leaves to Hold Third Quarter 2023 Conference Call on Thursday, November 9, 2023 at 5:00 p.m. ET

      TOCANCIPÁ, Colombia, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Clever Leaves Holdings Inc. (NASDAQ:CLVR, CLVRW))) ("Clever Leaves" or the "Company"), a global medicinal cannabis company, will hold a conference call on Thursday, November 9, 2023 at 5:00 p.m. Eastern time to discuss its results for the third quarter ended September 30, 2023. The Company will provide its financial results in a press release prior to the conference call. Clever Leaves management will host the conference call, followed by a question-and-answer session. Conference Call Date: Thursday, November 9, 2023Time: 5:00 p.m. Eastern timeToll-free dial-in number: 1-855-238-2333International dial-in number: 1-412-317-5222Confere

      11/2/23 8:30:00 AM ET
      $CLVR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Clever Leaves Reports Second Quarter 2023 Results

      - Total Revenue Increased 21% Year-Over-Year, Driven by 151% Year-Over-Year Growth in Cannabinoid Revenue - - Continued Expense Reductions Drive Improved Adjusted EBITDA Performance of ($2.1) Million - - July 2023 Sale of Portuguese Processing Assets Added $2.7 Million in Cash Following the End of Q2 - - Reaffirming Previously Announced 2023 Guidance - TOCANCIPÁ, Colombia, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Clever Leaves Holdings Inc. (NASDAQ:CLVR, CLVRW))) ("Clever Leaves" or the "Company"), a global medicinal cannabis company, is reporting financial and operating results for the second quarter ended June 30, 2023. All financial information is provided in US dollars unless otherwise in

      8/14/23 4:01:00 PM ET
      $CLVR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CLVR
    Leadership Updates

    Live Leadership Updates

    See more
    • Clever Leaves Reminds Shareholders of its Upcoming Annual Meeting on June 2, 2023

      TOCANCIPÁ, Colombia, May 26, 2023 (GLOBE NEWSWIRE) -- Clever Leaves Holdings Inc. (NASDAQ:CLVR, CLVRW))) ("Clever Leaves" or the "Company"), a global medicinal cannabis company, reminds shareholders that it will hold its 2023 Annual Meeting of Shareholders (the "Annual Meeting") on Friday, June 2, 2023 at 10:00 a.m. Eastern Time. The Annual Meeting will be in a virtual-only format. Clever Leaves reminds investors that its board has recommended that shareholders vote "FOR" the proposal to elect each of the five (5) nominees named in the proxy statement to the Board of Directors, "FOR" the appointment of Marcum LLP as the Company's independent registered public accounting firm to serve as in

      5/26/23 8:30:00 AM ET
      $CLVR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Clever Leaves Appoints William Muecke to Board of Directors

      BOCA RATON, Fla., March 17, 2022 (GLOBE NEWSWIRE) -- Clever Leaves Holdings Inc. (NASDAQ:CLVR, CLVRW))) ("Clever Leaves" or the "Company"), a leading multinational operator and licensed producer of pharmaceutical-grade cannabinoids, announced that it has appointed William Muecke to its board of directors, effective March 25, 2022, to fill the vacancy resulting from the previously announced departure of Kyle Detwiler, the Company's current chairman and CEO, effective March 24, 2022. Muecke was also appointed to the board's nominating and governance committee, as well as its compensation committee. Muecke is a co-founder and managing member of Artemis Growth Partners, an impact-focused ESG

      3/17/22 8:30:00 AM ET
      $CLVR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Clever Leaves Announces Leadership Transition Plan

      BOCA RATON, Fla., Feb. 09, 2022 (GLOBE NEWSWIRE) -- Clever Leaves Holdings Inc. (NASDAQ:CLVR, CLVRW))) ("Clever Leaves" or the "Company"), a leading multinational operator and licensed producer of pharmaceutical-grade cannabinoids, today announced a leadership transition plan. Andres Fajardo, currently a director and president of the Company, has been selected to succeed Kyle Detwiler as CEO, effective March 24, 2022. Detwiler will remain CEO until March 24, 2022, to ensure a smooth transition, and he will continue to serve as the Company's Chairman until such date. "Today's leadership changes are the culmination of a succession planning process that our board and Kyle have worked on tog

      2/9/22 7:59:00 AM ET
      $CLVR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CLVR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • New insider Bcm Investimentos Fundo De Investimento Multimercado Credito Privado Investimento No Exterior claimed ownership of 322,234 shares (SEC Form 3)

      3 - Clever Leaves Holdings Inc. (0001819615) (Issuer)

      5/21/24 8:07:09 PM ET
      $CLVR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Hague Henry R Iii sold $563 worth of shares (170 units at $3.31), decreasing direct ownership by 1% to 11,951 units (SEC Form 4)

      4 - Clever Leaves Holdings Inc. (0001819615) (Issuer)

      3/12/24 4:50:10 PM ET
      $CLVR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Hague Henry R Iii sold $1,623 worth of shares (411 units at $3.95), decreasing direct ownership by 3% to 12,121 units (SEC Form 4)

      4 - Clever Leaves Holdings Inc. (0001819615) (Issuer)

      2/29/24 4:01:46 PM ET
      $CLVR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CLVR
    SEC Filings

    See more
    • SEC Form 15-12G filed by Clever Leaves Holdings Inc.

      15-12G - Clever Leaves Holdings Inc. (0001819615) (Filer)

      5/16/24 4:45:21 PM ET
      $CLVR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Clever Leaves Holdings Inc.

      EFFECT - Clever Leaves Holdings Inc. (0001819615) (Filer)

      5/9/24 12:15:20 AM ET
      $CLVR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 POS filed by Clever Leaves Holdings Inc.

      S-8 POS - Clever Leaves Holdings Inc. (0001819615) (Filer)

      5/6/24 4:15:58 PM ET
      $CLVR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CLVR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Canaccord Genuity reiterated coverage on Clever Leaves Holdings with a new price target

      Canaccord Genuity reiterated coverage of Clever Leaves Holdings with a rating of Buy and set a new price target of $10.00 from $12.00 previously

      12/23/21 7:40:56 AM ET
      $CLVR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Canaccord Genuity reiterated coverage on Clever Leaves Holdings with a new price target

      Canaccord Genuity reiterated coverage of Clever Leaves Holdings with a rating of Buy and set a new price target of $12.00 from $13.00 previously

      11/12/21 8:49:58 AM ET
      $CLVR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Canaccord Genuity initiated coverage on Clever Leaves Holdings with a new price target

      Canaccord Genuity initiated coverage of Clever Leaves Holdings with a rating of Buy and set a new price target of $13.00

      7/27/21 7:11:17 AM ET
      $CLVR
      Biotechnology: Pharmaceutical Preparations
      Health Care